Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Alao, John P ^a   Stavropoulou, Alexandra V ^a   Lam, Eric W F ^a   Coombes, R Charles ^a   Vigushin, David M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEASOME; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; THREONINE; TRICHOSTATIN A; UBIQUITIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL NUCLEUS; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG TARGETING; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEAR EXPORT SIGNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UBIQUITINATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 33644836891     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-8     Document Type: Article

References (35)

1. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512.
2. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13(12):1501-1512.
3. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7:812-821.
4. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW: Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005, 24:2599-2612.
5. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
6. Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000, 14:3102-3114.
7. Alt JR, Gladden AB, Diehl JA: p21 (Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 2002, 277:8517-8523.
8. Diehl JA, Zindy F, Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997, 11:957-972.
9. Germain D, Russell A, Thompson A, Hendley J: Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem 2000, 275:12074-12079.
10. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003, 278:30339-30347.
11. Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000, 102:55-66.
12. Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E: Mirk/dyrk 1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem 2004, 279:27790-27798.
13. Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D: Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 1999, 18:1983-1991.
14. Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A 1998, 95:11324-11329.
15. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M: Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004, 428:190-193.
16. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004, 10:8094-8104.
17. Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, Mani S: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 2002, 1:695-706.
18. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
19. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS: Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005, 67:1342-1348.
20. Arnold A, Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005, 23:4215-4224.
21. Marson A, Lawn RM, Mikita T: Oxidized low density lipoprotein blocks lipopolysaccharide-induced interferon beta synthesis in human macrophages by interfering with IRF3 activation. J Biol Chem 2004, 279:28781-28788.
22. Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4: 13-18.
23. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528.
24. Marson CM, Serradji N, Rioja AS, Gastaud SP, Alao JP, Coombes RC, Vigushin DM: Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett 2004, 14:2477-2481.
25. Richardson PG: A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 2004, 5:1321-1331.
26. Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
27. Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397-403.
28. Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR: Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 2004, 279:41504-41511.
29. Ganiatsas S, Dow R, Thompson A, Schulman B, Germain D: A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene 2001, 20:3641-3650.
30. Wojcik C, DeMartino GN: Intracellular localization of proteasomes. Int J Biochem Cell Biol 2003, 35:579-589.
31. Tawa NEJ, Odessey R, Goldberg AL: Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997, 100:197-203.
32. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem 1997, 272:28479-28484.
33. Cotelle V, Meek SE, Provan F, Milne FC, Morrice N, MacKintosh C: 14-3-3s regulate global cleavage of their diverse binding partners in sugar-starved Arabidopsis cells. Embo J 2000, 19:2869-2876.
34. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL: Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002, 62:6916-6923.
35. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004, 90:1942-1948.